Cargando…

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity

Semi-synthetic triterpenoids are antioxidant inflammation modulator (AIM) compounds that inhibit tumor cell growth and metastasis. Compounds in the AIM class bind to Keap1 and attenuate Nrf2 degradation. In the nucleus, Nrf2 increases antioxidant gene expression and reduces pro-inflammatory gene exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Probst, Brandon L., Trevino, Isaac, McCauley, Lyndsey, Bumeister, Ron, Dulubova, Irina, Wigley, W. Christian, Ferguson, Deborah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405374/ https://www.ncbi.nlm.nih.gov/pubmed/25897966 http://dx.doi.org/10.1371/journal.pone.0122942

Ejemplares similares

Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405
por: Probst, Brandon L., et al.
Publicado: (2015)

The synthetic triterpenoid, RTA405, increases glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
por: Ding, Yanfeng, et al.
Publicado: (2012)

A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE
por: Wei, Hsi-Ju, et al.
Publicado: (2017)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
por: Creelan, Ben C, et al.
Publicado: (2017)

Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects
por: Zighan, Madleen, et al.
Publicado: (2022)

The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling
por: Sun, Xuewu, et al.
Publicado: (2019)

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers
por: Reisman, Scott A., et al.
Publicado: (2015)

The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H(2)O(2)-induced cell injury via NF-E2-related factor 2 (Nrf2) activation
por: Liu, Xiaobin, et al.
Publicado: (2015)

RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene
por: Han, Peng, et al.
Publicado: (2017)

Mechanisms and therapeutic implications of RTA 408, an activator of Nrf2, in subarachnoid hemorrhage–induced delayed cerebral vasospasm and secondary brain injury
por: Tsai, Tai-Hsin, et al.
Publicado: (2020)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease()
por: Aminzadeh, Mohammad A., et al.
Publicado: (2013)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
por: Aminzadeh, Mohammad A., et al.
Publicado: (2014)

RTA‐408 protects against propofol‐induced cognitive impairment in neonatal mice via the activation of Nrf2 and the inhibition of NF‐κB p65 nuclear translocation
por: Zhang, Ling, et al.
Publicado: (2020)

RTA 408 Inhibits Interleukin-1β-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent NF-κB and AP-1 Activation in Rat Brain Astrocytes
por: Yang, Chien-Chung, et al.
Publicado: (2019)

Nanoformulations for Delivery of Pentacyclic Triterpenoids in Anticancer Therapies
por: Kaps, Anna, et al.
Publicado: (2021)

Initial Commissioning Results of the RTA Injector
por: Eylon, S, et al.
Publicado: (1999)

At R407/R408
Publicado: (1974)

Ursolic Acid and Related Analogues: Triterpenoids with Broad Health Benefits
por: Nguyen, Huynh Nga, et al.
Publicado: (2021)

KSHV Rta Promoter Specification and Viral Reactivation
por: Guito, Jonathan, et al.
Publicado: (2012)

Ov2 is a modulator of OvHV-2 RTA mediated gene expression
por: Dry, Inga, et al.
Publicado: (2019)

Partners in crime: MicroRNA408 and peptide miPEP408 negatively regulate arsenic and low sulfur tolerance
por: Ku, Yee-Shan
Publicado: (2023)

Suppressive Regulation of KSHV RTA with O-GlcNAcylation
por: Ko, Ying-Chieh, et al.
Publicado: (2012)

Memorandum: plans of experiment R 407-408
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1974)

Memorandum: Collaboration between Experiments 407 and 408
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1973)

Biological Evaluation and Docking Studies of Synthetic Oleanane-type Triterpenoids
por: Ortega-Muñoz, Mariano, et al.
Publicado: (2018)

A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA
por: Doodnauth, Andrew V., et al.
Publicado: (2021)

Virtual Palliative Care Is Inclusive Care (QI408)
por: Damiano, Sara, et al.
Publicado: (2022)

408 Quality by Design: A Framework for Study Success
por: Orechwa, Allison, et al.
Publicado: (2023)

Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR
por: Yore, Mark M., et al.
Publicado: (2011)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

Role of Pentacyclic Triterpenoids in Chemoprevention and Anticancer Treatment: An Overview on Targets and Underling Mechanisms
por: Ghante, Mahavir H., et al.
Publicado: (2019)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

Pentacyclic Triterpenoid Phytochemicals with Anticancer Activity: Updated Studies on Mechanisms and Targeted Delivery
por: Nistor, Madalina, et al.
Publicado: (2023)

Thermodynamics of RTA3 peptide binding to membranes and consequences for antimicrobial activity()
por: Hawrani, Ayman, et al.
Publicado: (2010)

Relativistic Klystron Two-Beam Accelerator Studies at the RTA Test Facility
por: Westenskow, G A, et al.
Publicado: (1996)

Role of TAF4 in Transcriptional Activation by Rta of Epstein-Barr Virus
por: Yang, Ya-Chun, et al.
Publicado: (2013)

Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment
por: Galbiati, Francesca
Publicado: (2020)

Robotic Transanal Total Mesorectal Excision (RTaTME): State of the Art
por: Rondelli, Fabio, et al.
Publicado: (2021)

Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription
por: Ali, Ahmed, et al.
Publicado: (2022)

NEPHROGENIC SYSTEMIC FIBROSIS: REVIEW OF 408 BIOPSY-CONFIRMED CASES
por: Zou, Zhitong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_n9k1bvn7k6p6dl48hbnj7lonia